

**Amendments to the Claims:**

Please amend the claims as follows. The following listing should replace all previous listings of the claims.

1. (Currently amended) A method for killing glioma cancer cells in a subject wherein said glioma cancer cells express malignin, said method comprising administering to said subject an effective amount of a first dosage of a composition comprising malignin ~~wherein said malignin is derived from glioblastoma brain tumor cells and~~ wherein said administration of said dosage stimulates the immune system of said subject to produce and release antimalignin antibody that binds and kills said glioma cancer cells ~~and is cytotoxic to said glioma cancer cells to kill said glioma cancer cells.~~
2. (Currently amended) The ~~process~~ method of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.
3. (Original) The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.
4. (Original) The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.
5. (Canceled).
6. (Withdrawn) An antimalignin antibody.
7. (Withdrawn) A device for removing cancer cells from the body of a subject, said device comprising cells having immunological specificity for malignin, recognin L or recognin M, wherein said device binds, absorbs or engulfs cancer cells which come into contact therewith.

8. (Withdrawn) The device of claim 7 wherein said device comprises a filter through which the cancer cells are passed.
9. (Withdrawn) The device of claim 7 wherein the device comprises a surface over which the cancer cells are passed.
10. (Withdrawn) The device of claim 7 wherein the device comprises a resin over which the cancer cells are passed.
11. (Withdrawn) The device of claim 7 wherein the cells are selected from the group consisting of T cells, B cells and phagocytes.
12. (Withdrawn) A process for ascertaining the presence of cells transformed to the malignant state in a subject
  - (1) obtaining a fluid or tissue specimen from the subject;
  - (2) quantifying the amounts of antimalignin antibody and/or immune cells having specificity for malignin, recognin L and/or recognin M in the fluid or tissue specimen;
  - (3) correlating the amounts to the presence of cells transformed to the malignant state.
13. (Withdrawn) An antimalignin antibody having a cytotoxic agent attached thereto.